In its statement, A2 said it was "well placed to cope with changes to infant formula regulations in China announced in recent months including taxation of cross-border e-commerce (CBEC) traded commodities, publication of product lists for CBEC traded commodities through China free-trade zones and an infant formula registration rule for domestic and imported infant formula products in China."
De Cesare said A2 is well placed to benefit from the increased Chinese scrutiny of the infant formula market.
"Companies with a quality product are going to benefit the most from the tightening up of this market, it will be the periphery, the lower-quality companies who will no longer be invited to the party."
A2 is due to join the S&P/ASX 200 Index at the close of trading on June 17 after a successful listing in Australia. De Cesare says the share register of A2 has broadened considerably in the last year and the inclusion in the ASX 200 will attract funds from around the world.
"When you combine the ASX listing which makes it investable for Australian funds and the second tick, with the inclusion in the ASX 200, that's the cherry on the cake, now they're in the flagship benchmark you get increasing interest from offshore, from North America, from the UK."